Clal Biotechnology reported ILS2.42M in Interest Expense on Debt for its fiscal quarter ending in September of 2020.


Interest Expense On Debt Change Date
Clal Biotechnology ILS 2.42M 640K Sep/2020
Compugen USD 1.28M 507K Sep/2024
Life Technologies USD 0 0 Sep/2024
RedHill Biopharma USD 89.8K 31.69M Jun/2024